Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

NIH 5OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1Dermatologic 1

Conditions

Uterine Cervical Neoplasms 1Melanoma 1

Interventions

Cyclophosphamide 548pembrolizumab 384Radiotherapy 363Bevacizumab 360Carboplatin 351Rituximab 315Cisplatin 300Gemcitabine 297Paclitaxel 288Dexamethasone 272Docetaxel 271fludarabine phosphate 241Doxorubicin 231Nivolumab 220Etoposide 209Cytarabine 203Lenalidomide 201fludarabine 191Oxaliplatin 191Fluorouracil 190Melphalan 189Filgrastim 188Capecitabine 175Calcium Dobesilate 172Radiosurgery 167Erlotinib Hydrochloride 167Methotrexate 163Bortezomib 162Granulocyte Colony-Stimulating Factor 154Whole-Body Irradiation 144

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Has results × GSK2141795 × Clear all
NCT01941927 2020-02-12

Trametinib With GSK2141795 in BRAF Wild-type Melanoma

University of California, San Francisco

Phase 2 Completed
20 enrolled 16 charts
Dermatologic

Melanoma

NCT01958112 2019-05-31

GSK1120212+GSK2141795 for Cervical Cancer

Dana-Farber Cancer Institute

Phase 2 Terminated
14 enrolled 10 charts
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡